en
E-mail us
Leadership Team
Scientific Advisory Board
Best Cdmo Companies
Alex M. Chen
Alex M. Chen, PhD
Co-founder, Chairman & CEO
X
Alex M. Chen, PhD
Alex M. Chen, PhD

Co-founder, Chairman & CEO

  • Pursued Ph.D. in Chemistry from Rutgers University


  • 8 years at Merck in R&D and manufacturing division


  • Supported physical characterization, API phase selection and evaluation of more than 50 compounds in all stages of development


  • Expertise in solid-state characterization, polymorphism, co-crystal screening, chiral resolution, and nanoparticle engineering


Robert Wenslow
Robert Wenslow, PhD
Co-founder, VP of BD – US & EU
X
Robert Wenslow, PhD
Robert Wenslow, PhD

Co-founder, VP of BD - US & EU


  • Ph.D. in Chemistry from Pennsylvania State University


  • 14 years at Merck in drug R&D, manufacturing and management


  • Expertise in solid-state NMR, maintaining direct responsibilities of solid-state NMR facility at Merck


  • Established first analytical research group in Ireland for Merck


Eva Deng
Eva Deng
Secretary of the Board & CFO
X
Eva Deng
Eva Deng

Secretary of the Board & CFO


  • Master degree in management from Tsinghua University


  • Qualified ACCA Member since 2008


  • With more than 20 years of financial management experience and rich overseas practical experience


Rositza Petrova
Rositza Petrova, PhD
Head of US-NJ Site
X
Rositza Petrova, PhD
Rositza Petrova, PhD

Head of US - NJ Site, CRO Business Unit


  • Ph.D. in Materials Science, Georgetown University (Studied chiral separation and crystallization in gels under Professor Jennifer Swift, Ph.D.)


  • Expert in API solid form screening/discovery, crystalline form selection, polymorphism and chiral separations by crystallization


  • 15 years working experience in Merck with various leadership position including Leader of API Development Support Group - Center for Materials Science and Engineering in Merck Manufacturing Division, and Analytical Project Leader - Merck Animal Health


Decheng Ma
Decheng Ma, PhD
CEO of Crystal Formulation Services
X
Decheng Ma, PhD
Decheng Ma, PhD

CEO of CDMO Business Unit (CFS)


  • Trained as Chemical Engineer at Lehigh Univ. (PhD) and Tsinghua Univ. (BS)


  • 22 years formulation development and CRO/CDMO/CMO vendor anagement experience at Merck (US) and MSD (China)


  • Expert on solid oral formulation development, analytical and clinical supply


  • Responsible for or supported over 30 new drug development, 4 of which were commercialized.



Feng Li
Feng Li, PhD
CSO of Crystal Formulation Services
X
Feng Li, PhD
Feng Li, PhD

CSO of CDMO Business Unit (CFS)


  • Trained as an engineer(mechanical leaning) at Penn State Univ. (PhD) and China Agricultural Univ. (BE)


  • Significant expertise on oral solid dosage, powder mechanics, dry granulation and pediatric formulation


  • 21 years Phase I-III formulation development experience at Merck (US). Involved in over 50 small molecule NCE drug product development, 15 of which were commercialized


Xiaoxia (Jessica) Chen
Xiaoxia (Jessica) Chen, PhD
CTO of Crystal Formulation Services
X
Xiaoxia (Jessica) Chen, PhD
Xiaoxia (Jessica) Chen, PhD

CTO of CDMO Business Unit (CFS)


  • Trained as Chemical Engineer (PhD, Univ. of Texas at Austin; BS and MS, Tsinghua University) and Pharmacometrics (MS, Univ. of Maryland at Baltimore)


  • Skilled in various delivery systems and unit operation


  • 18 years preformulation, formulation (preclinical-III) and process development, regulatory filing and product commercialization experience at Roche, Abbott, Merck, Sunovion and Sage Therapeutics. Involved in over 35 early phase and 7 commercial products development


Yongqiang Li
Yongqiang Li, PhD
CEO of Candoo Pharmatech (Crystal Pharmatech's Canadian subsidiary)
X
Yongqiang Li, PhD
Yongqiang Li, PhD

CEO of Candoo Pharmatech (Crystal Pharmatech's Canadian subsidiary)


  • PhD degree in Pharmaceutics and Drug Delivery from Faculty of Pharmacy, University of Toronto, Canada


  • 19 years of formulation development and management experiences in innovative and generic pharmaceutical industries


  • Developed more than 30 products for global markets including many First-to-Files, NCE, 505 b(2) and First-to-Markets


  • Expertise in the development of complex oral delivery systems of immediate and controlled release, solubility/permeability enhancement, peptide delivery, bioequivalence, and alignment between nonclinical and clinical formulations for NCE drugs


Best Cdmo Companies
Dr. Elizabeth Vadas
InSciTech Inc.
X
Dr. Elizabeth Vadas
Dr. Elizabeth Vadas
  • 22-year experience at Merck Frosst, former head of Department of Pharmaceutical Research and Development, responsible from early compound characterization to formulation and process development of new chemical entities including the supply of clinical trial materials from phase I through phase III and technical transfer to manufacturing


  • Key contributor on formulation development of SINGULAIR® and several other products that lead to worldwide regulatory approval


  • Past president of CSPS, elected Fellow of AAPS and Fellow of CSPS, adjunct professor of pharmaceutics at the University of Montreal


Prof. Naír Rodríguez-Hornedo
University of Michigan
X
Prof. Naír Rodríguez-Hornedo
Prof. Naír Rodríguez-Hornedo
  • Developed a research program based on molecular-mechanistic approaches, founded on the premise that the concepts of supramolecular chemistry and crystal engineering


  • Serve on the FDA Advisory Committee for Pharmaceutical Sciences


  • Serve on the editorial boards of Crystal Growth and Design, Molecular Pharmaceutics and Journal of Pharmaceutical Sciences


  • Awards include Ebert Prize for the best article published in the Journal of Pharmaceutical Sciences in 2005


Prof. Lian Yu
University of Wisconsin
X
Prof. Lian Yu
Prof. Lian Yu
  • Leading researcher on solid-state chemistry


  • Research areas focused on polymorphism, crystallization of organic glasses, and molecular motions in solids


  • Honors include Elected Fellow of AAPS, Lilly Research Laboratories President's Award, and Invited Visiting Professorship at the University of Manchester, and David Grant Research Achievement Award in Physical Pharmacy from American Association of Pharmaceutical Scientists


Dr. Russell Outcalt
R. Outcalt Consulting, LLC
X
Dr. Russell Outcalt
Dr. Russell Outcalt
  • Pursued Ph.D. in Chemistry from Rutgers University


  • 8 years at Merck in R&D and manufacturing division


  • Supported physical characterization, API phase selection and evaluation of more than 50 compounds in all stages of development


  • Expert in solid-state characterization, polymorphism, co-crystal screening, chiral resolution, and nanoparticle engineering


Contact Us
bd_global@crystalpharmatech.com +1-609-604-8303
U.S
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
Canada
6800 Kitimat Rd, Unit 1, Mississauga, Ontario, Canada L5N 5M1
China
Suite B4-101, Biobay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, China, 215123
Suite 500-B, 3000 Eastpark Blvd, Cranbury, New Jersey 08512, USA
bd_global@crystalpharmatech.com +1-609-604-8303